On this basis, we explored potential anti‐renal fibrosis agents that target METTL3 and investigated their functions through molecular docking combined with high‐throughput drug virtual screening as well as pharmacological studies based on the structure of the METTL3 protein and the database of TCM monomers. The gene discussed is METTL3; the disease is renal fibrosis.